Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Melanoma

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 71 articles: HTML format Text format

Single Articles

August 2018
1. KUCHERLAPATI M
   Examining transcriptional changes to DNA replication and repair factors over uveal melanoma subtypes.
   BMC Cancer. 2018;18:818.
   PubMed     Text format     Abstract available
   
   
   July 2018
2. MCEVOY AC, Warburton L, Al-Ogaili Z, Celliers L, et al
   Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.
   BMC Cancer. 2018;18:726.
   PubMed     Text format     Abstract available
   
   
   
3. AMINI-ADLE M, Khanafer N, Le-Bouar M, Duru G, et al
   Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
   BMC Cancer. 2018;18:705.
   PubMed     Text format     Abstract available
   
   
   June 2018
4. XIAO J, Egger ME, McMasters KM, Hao H, et al
   Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
   BMC Cancer. 2018;18:675.
   PubMed     Text format     Abstract available
   
   
   
5. INOUE K, Tsubamoto H, Isono-Nakata R, Sakata K, et al
   Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report.
   BMC Cancer. 2018;18:630.
   PubMed     Text format     Abstract available
   
   
   May 2018
6. GUIDA M, Tommasi S, Strippoli S, Natalicchio MI, et al
   The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
   BMC Cancer. 2018;18:552.
   PubMed     Text format     Abstract available
   
   
   
7. MCDONALD MA, Sanghvi P, Bykowski J, Daniels GA, et al
   Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
   BMC Cancer. 2018;18:549.
   PubMed     Text format     Abstract available
   
   
   
8. SI L, Zhang X, Xu Z, Jiang Q, et al
   Vemurafenib in Chinese patients with BRAF(V600) mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.
   BMC Cancer. 2018;18:520.
   PubMed     Text format     Abstract available
   
   
   April 2018
9. VOSOUGHI E, Lee JM, Miller JR, Nosrati M, et al
   Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
   BMC Cancer. 2018;18:490.
   PubMed     Text format     Abstract available
   
   
   
10. LI Y, Zhang J, Liu Y, Zhang B, et al
    MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells.
    BMC Cancer. 2018;18:404.
    PubMed     Text format     Abstract available
    
    
    February 2018
11. SOOTICHOTE R, Thuwajit P, Singsuksawat E, Warnnissorn M, et al
    Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC Cancer. 2018;18:231.
    PubMed     Text format     Abstract available
    
    
    
12. MA Q, Shilkrut M, Zhao Z, Li M, et al
    Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data.
    BMC Cancer. 2018;18:145.
    PubMed     Text format     Abstract available
    
    
    
13. ZAGER JS, Gastman BR, Leachman S, Gonzalez RC, et al
    Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    BMC Cancer. 2018;18:130.
    PubMed     Text format     Abstract available
    
    
    January 2018
14. BUDDEN T, van der Westhuizen A, Bowden NA
    Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.
    BMC Cancer. 2018;18:100.
    PubMed     Text format     Abstract available
    
    
    
15. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Text format     Abstract available
    
    
    
16. KIKULSKA A, Rausch T, Krzywinska E, Pawlak M, et al
    Coordinated expression and genetic polymorphisms in Grainyhead-like genes in human non-melanoma skin cancers.
    BMC Cancer. 2018;18:23.
    PubMed     Text format     Abstract available
    
    
    December 2017
17. SONG L, McNeil EM, Ritchie AM, Astell KR, et al
    Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase zeta.
    BMC Cancer. 2017;17:864.
    PubMed     Text format     Abstract available
    
    
    
18. KUZBICKI L, Lange D, Stanek-Widera A, Chwirot BW, et al
    Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
    BMC Cancer. 2017;17:854.
    PubMed     Text format     Abstract available
    
    
    November 2017
19. OZAKI Y, Shindoh J, Miura Y, Nakajima H, et al
    Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.
    BMC Cancer. 2017;17:778.
    PubMed     Text format     Abstract available
    
    
    
20. CIRILO PDR, de Sousa Andrade LN, Correa BRS, Qiao M, et al
    MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
    BMC Cancer. 2017;17:750.
    PubMed     Text format     Abstract available
    
    
    
21. CHAGANI S, Wang R, Carpenter EL, Lohr CV, et al
    Ablation of epidermal RXRalpha in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas.
    BMC Cancer. 2017;17:736.
    PubMed     Text format     Abstract available
    
    
    October 2017
22. MIDDLETON MR, Atkins MB, Amos K, Wang PF, et al
    Societal preferences for adjuvant melanoma health states: UK and Australia.
    BMC Cancer. 2017;17:689.
    PubMed     Text format     Abstract available
    
    
    September 2017
23. VAN DER HIEL B, Haanen JBAG, Stokkel MPM, Peeper DS, et al
    Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter st
    BMC Cancer. 2017;17:649.
    PubMed     Text format     Abstract available
    
    
    August 2017
24. FALKENIUS J, Johansson H, Tuominen R, Frostvik Stolt M, et al
    Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
    BMC Cancer. 2017;17:584.
    PubMed     Text format     Abstract available
    
    
    
25. DE SMEDT J, Van Kelst S, Boecxstaens V, Stas M, et al
    Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
    BMC Cancer. 2017;17:562.
    PubMed     Text format     Abstract available
    
    
    
26. HARRER DC, Simon B, Fujii SI, Shimizu K, et al
    RNA-transfection of gamma/delta T cells with a chimeric antigen receptor or an alpha/beta T-cell receptor: a safer alternative to genetically engineered alpha/beta T cells for the immunotherapy of melanoma.
    BMC Cancer. 2017;17:551.
    PubMed     Text format     Abstract available
    
    
    
27. HEPPT MV, Siepmann T, Engel J, Schubert-Fritschle G, et al
    Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    BMC Cancer. 2017;17:536.
    PubMed     Text format     Abstract available
    
    
    June 2017
28. GAUSTAD JV, Simonsen TG, Andersen LMK, Rofstad EK, et al
    Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts.
    BMC Cancer. 2017;17:411.
    PubMed     Text format     Abstract available
    
    
    May 2017
29. LI X, Li Z, Li X, Liu B, et al
    Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.
    BMC Cancer. 2017;17:357.
    PubMed     Text format     Abstract available
    
    
    
30. GAMBICHLER T, Strutzmann S, Tannapfel A, Susok L, et al
    Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
    BMC Cancer. 2017;17:327.
    PubMed     Text format     Abstract available
    
    
    March 2017
31. BHANGOO MS, Zhou JY, Ali SM, Madison R, et al
    Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.
    BMC Cancer. 2017;17:197.
    PubMed     Text format     Abstract available
    
    
    February 2017
32. REIMAN A, Kikuchi H, Scocchia D, Smith P, et al
    Validation of an NGS mutation detection panel for melanoma.
    BMC Cancer. 2017;17:150.
    PubMed     Text format     Abstract available
    
    
    January 2017
33. MERZOUG-LARABI M, Spasojevic C, Eymard M, Hugonin C, et al
    Protein kinase C inhibitor Go6976 but not Go6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1.
    BMC Cancer. 2017;17:12.
    PubMed     Text format     Abstract available
    
    
    
34. O'SHEA SJ, Rogers Z, Warburton F, Ramirez AJ, et al
    Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study.
    BMC Cancer. 2017;17:5.
    PubMed     Text format     Abstract available
    
    
    December 2016
35. CAISOVA V, Vieru A, Kumzakova Z, Glaserova S, et al
    Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.
    BMC Cancer. 2016;16:940.
    PubMed     Text format     Abstract available
    
    
    
36. SCHOFFER O, Schulein S, Arand G, Arnholdt H, et al
    Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011.
    BMC Cancer. 2016;16:936.
    PubMed     Text format     Abstract available
    
    
    November 2016
37. SCHIROSI L, Strippoli S, Gaudio F, Graziano G, et al
    Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
    BMC Cancer. 2016;16:905.
    PubMed     Text format     Abstract available
    
    
    
38. CHIEN CH, Lee MJ, Liou HC, Liou HH, et al
    Growth hormone is increased in the lungs and enhances experimental lung metastasis of melanoma in DJ-1 KO mice.
    BMC Cancer. 2016;16:871.
    PubMed     Text format     Abstract available
    
    
    January 2016
39. CHEN WL, Pan L, Kinghorn AD, Swanson SM, et al
    Silvestrol induces early autophagy and apoptosis in human melanoma cells.
    BMC Cancer. 2016;16:17.
    PubMed     Text format     Abstract available
    
    
    
40. JAYACHANDRAN A, Lo PH, Chueh AC, Prithviraj P, et al
    Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells.
    BMC Cancer. 2016;16:134.
    PubMed     Text format     Abstract available
    
    
    
41. AFASIZHEVA A, Devine A, Tillman H, Fung KL, et al
    Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival.
    BMC Cancer. 2016;16:186.
    PubMed     Text format     Abstract available
    
    
    
42. LI H, Pedersen L, Norgaard M, Ulrichsen SP, et al
    The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
    BMC Cancer. 2016;16:295.
    PubMed     Text format     Abstract available
    
    
    
43. KUCEROVA L, Demkova L, Skolekova S, Bohovic R, et al
    Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation.
    BMC Cancer. 2016;16:308.
    PubMed     Text format     Abstract available
    
    
    
44. PISANO M, Palomba A, Tanca A, Pagnozzi D, et al
    Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6.
    BMC Cancer. 2016;16:317.
    PubMed     Text format     Abstract available
    
    
    
45. POUKKA M, Bykachev A, Siiskonen H, Tyynela-Korhonen K, et al
    Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.
    BMC Cancer. 2016;16:313.
    PubMed     Text format     Abstract available
    
    
    
46. SHEN W, Sakamoto N, Yang L
    Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis.
    BMC Cancer. 2016;16:413.
    PubMed     Text format     Abstract available
    
    
    
47. YU Y, Huang R, Zong X, He X, et al
    INFalpha-2b inhibitory effects on CD4+CD25+FOXP3+ regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
    BMC Cancer. 2016;16:397.
    PubMed     Text format     Abstract available
    
    
    
48. ERIM Y, Scheel J, Breidenstein A, Metz CH, et al
    Psychosocial impact of prognostic genetic testing in the care of uveal melanoma patients: protocol of a controlled prospective clinical observational study.
    BMC Cancer. 2016;16:408.
    PubMed     Text format     Abstract available
    
    
    
49. CAMPION CA, Soden D, Forde PF
    Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models.
    BMC Cancer. 2016;16:462.
    PubMed     Text format     Abstract available
    
    
    
50. ANGELINO G, De Pasquale MD, De Sio L, Serra A, et al
    NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications.
    BMC Cancer. 2016;16:512.
    PubMed     Text format     Abstract available
    
    
    
51. SINNBERG T, Wang J, Sauer B, Schittek B, et al
    Casein kinase 1alpha has a non-redundant and dominant role within the CK1 family in melanoma progression.
    BMC Cancer. 2016;16:594.
    PubMed     Text format     Abstract available
    
    
    
52. FENG Y, Zhao J, Yang Q, Xiong W, et al
    Pulmonary melanoma and "crazy paving" patterns in chest images: a case report and literature review.
    BMC Cancer. 2016;16:592.
    PubMed     Text format     Abstract available
    
    
    
53. LUKIC M, Jareid M, Weiderpass E, Braaten T, et al
    Coffee consumption and the risk of malignant melanoma in the Norwegian Women and Cancer (NOWAC) Study.
    BMC Cancer. 2016;16:562.
    PubMed     Text format     Abstract available
    
    
    
54. MALEKA A, Astrom G, Bystrom P, Ullenhag GJ, et al
    A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.
    BMC Cancer. 2016;16:634.
    PubMed     Text format     Abstract available
    
    
    
55. DIAZ-NUNEZ M, Diez-Torre A, De Wever O, Andrade R, et al
    Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
    BMC Cancer. 2016;16:667.
    PubMed     Text format     Abstract available
    
    
    
56. WANG Y, Zhao Y, Ma S
    Racial differences in six major subtypes of melanoma: descriptive epidemiology.
    BMC Cancer. 2016;16:691.
    PubMed     Text format     Abstract available
    
    
    
57. GRASSO C, Anaka M, Hofmann O, Sompallae R, et al
    Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations.
    BMC Cancer. 2016;16:726.
    PubMed     Text format     Abstract available
    
    
    May 2015
58. KIM DW, Barcena E, Mehta UN, Rohlfs ML, et al
    Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.
    BMC Cancer. 2015;15:400.
    PubMed     Text format     Abstract available
    
    
    January 2015
59. CARVAJAL RD, Schwartz GK, Mann H, Smith I, et al
    Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
    BMC Cancer. 2015;15:467.
    PubMed     Text format     Abstract available
    
    
    
60. MAGNUSSEN GI, Emilsen E, Giller Fleten K, Engesaeter B, et al
    Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.
    BMC Cancer. 2015;15:462.
    PubMed     Text format     Abstract available
    
    
    
61. HELIAS-RODZEWICZ Z, Funck-Brentano E, Baudoux L, Jung CK, et al
    Variations of BRAF mutant allele percentage in melanomas.
    BMC Cancer. 2015;15:497.
    PubMed     Text format     Abstract available
    
    
    
62. HAUSWALD H, Stenke A, Debus J, Combs SE, et al
    Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma.
    BMC Cancer. 2015;15:537.
    PubMed     Text format     Abstract available
    
    
    
63. LI W, Yu Y, Wang H, Yan A, et al
    Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis.
    BMC Cancer. 2015;15:758.
    PubMed     Text format     Abstract available
    
    
    
64. FARIAS CF, Massaoka MH, Girola N, Azevedo RA, et al
    Benzofuroxan derivatives N-Br and N-I induce intrinsic apoptosis in melanoma cells by regulating AKT/BIM signaling and display anti metastatic activity in vivo.
    BMC Cancer. 2015;15:807.
    PubMed     Text format     Abstract available
    
    
    
65. PASINI L, Re A, Tebaldi T, Ricci G, et al
    TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines.
    BMC Cancer. 2015;15:777.
    PubMed     Text format     Abstract available
    
    
    
66. MILES SL, Fischer AP, Joshi SJ, Niles RM, et al
    Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells.
    BMC Cancer. 2015;15:867.
    PubMed     Text format     Abstract available
    
    
    
67. WEISS S, Darvishian F, Tadepalli J, Shapiro R, et al
    Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis.
    BMC Cancer. 2015;15:926.
    PubMed     Text format     Abstract available
    
    
    
68. VENDITTI O, De Lisi D, Caricato M, Caputo D, et al
    Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis.
    BMC Cancer. 2015;15:87.
    PubMed     Text format     Abstract available
    
    
    
69. CAPPETTA M, Berdasco M, Hochmann J, Bonilla C, et al
    Effect of genetic ancestry on leukocyte global DNA methylation in cancer patients.
    BMC Cancer. 2015;15:434.
    PubMed     Text format     Abstract available
    
    
    
70. VASKOVICOVA K, Szabadosova E, Cermak V, Gandalovicova A, et al
    PKCalpha promotes the mesenchymal to amoeboid transition and increases cancer cell invasiveness.
    BMC Cancer. 2015;15:326.
    PubMed     Text format     Abstract available
    
    
    
71. MOK S, Tsoi J, Koya RC, Hu-Lieskovan S, et al
    Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    BMC Cancer. 2015;15:356.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: